ReNeuron Group Stock Price, News & Analysis (LON:RENE)

GBX 1.56 0.01 (0.65 %)
(As of 01/18/2018 07:05 AM ET)
Previous CloseGBX 1.55
Today's RangeGBX 1.50 - GBX 1.57
52-Week RangeGBX 1.52 - GBX 2.75
Volume2.74 million shs
Average Volume1.76 million shs
Market Capitalization£42.75 million
P/E Ratio-155.95
Dividend YieldN/A
BetaN/A

About ReNeuron Group (LON:RENE)

ReNeuron Group logoReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.

Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorBiotechnology & Medical Research - NEC
SymbolLON:RENE
CUSIPN/A
Phone+44-20-38198400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-155.95
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX (0.01)
Net IncomeN/A
Net Margins-32,825.00%
Return on Equity-27.66%
Return on Assets-25.36%

Miscellaneous

EmployeesN/A
Outstanding Shares3,160,000,000

ReNeuron Group (LON:RENE) Frequently Asked Questions

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How were ReNeuron Group's earnings last quarter?

ReNeuron Group Plc (LON:RENE) issued its quarterly earnings data on Thursday, December, 14th. The company reported ($0.30) earnings per share (EPS) for the quarter. The business earned $0.02 million during the quarter. ReNeuron Group had a negative net margin of 32,825.00% and a negative return on equity of 27.66%. View ReNeuron Group's Earnings History.

Where is ReNeuron Group's stock going? Where will ReNeuron Group's stock price be in 2018?

1 Wall Street analysts have issued twelve-month price objectives for ReNeuron Group's stock. Their predictions range from GBX 9 to GBX 13. On average, they anticipate ReNeuron Group's share price to reach GBX 11 in the next twelve months. View Analyst Ratings for ReNeuron Group.

Who are some of ReNeuron Group's key competitors?

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the folowing people:

  • Olav Hellebo, Chief Executive Officer, Director
  • Michael Elliott Hunt, Chief Financial Officer, Executive Director, Company Secretary
  • John D. Sinden Ph.D., Chief Scientific Officer, Executive Director (Age 62)
  • Sharon Grimster, Vice President Development and General Manager, Wales
  • Randolph Corteling, Head of Research
  • Julian Howell, Chief Medical Officer
  • Shaun Stapleton, Head - Regulatory Affairs
  • John Edward Berriman, Non-Executive Chairman of the Board (Age 68)
  • Simon Christopher Cartmell, Non-Executive Director (Age 47)
  • Timothy Henry Corn, Non-Executive Director (Age 64)

How do I buy ReNeuron Group stock?

Shares of ReNeuron Group and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ReNeuron Group's stock price today?

One share of ReNeuron Group stock can currently be purchased for approximately GBX 1.56.

How big of a company is ReNeuron Group?

ReNeuron Group has a market capitalization of £42.75 million.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.


MarketBeat Community Rating for ReNeuron Group (RENE)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  98 (Vote Outperform)
Underperform Votes:  38 (Vote Underperform)
Total Votes:  136
MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ReNeuron Group (LON:RENE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 11GBX 11GBX 12GBX 12

ReNeuron Group (LON:RENE) Consensus Price Target History

Price Target History for ReNeuron Group (LON:RENE)

ReNeuron Group (LON:RENE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/9/2017Stifel NicolausReiterated RatingBuyGBX 13View Rating Details
10/31/2017N+1 SingerReiterated RatingcorporateView Rating Details
(Data available from 1/18/2016 forward)

Earnings

ReNeuron Group (LON:RENE) Earnings History and Estimates Chart

Earnings by Quarter for ReNeuron Group (LON:RENE)

ReNeuron Group (LON RENE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/14/2017S1 2018GBX (0.30)GBX 2 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

ReNeuron Group (LON:RENE) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for ReNeuron Group (LON:RENE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ReNeuron Group (LON RENE) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for ReNeuron Group (LON:RENE)

ReNeuron Group (LON RENE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2017Michael HuntInsiderBuy250,000GBX 3£7,500
2/17/2016Hunt,MichaelInsiderSell509,554GBX 3£15,286.62
2/12/2016Hunt,MichaelInsiderSell594,637GBX 3£17,839.11
2/11/2016Hunt,MichaelInsiderSell1,208,333GBX 3£36,249.99
2/5/2016Hunt,MichaelInsiderSell1,035,533GBX 3£31,065.99
2/2/2016Edward Berriman,JohnInsiderBuy318,476GBX 3£9,554.28
1/29/2015Olav HellebøInsiderBuy322,778GBX 3.10£10,006.12
(Data available from 1/1/2013 forward)

Headlines

ReNeuron Group (LON RENE) News Headlines

Source:
DateHeadline
Proposed Share Capital Reorganisation - London South East (blog)Proposed Share Capital Reorganisation - London South East (blog)
www.lse.co.uk - January 5 at 4:31 PM
ReNeuron Groups (RNUGF) CEO Olav Hellebø on Q2 2018 Results - Earnings Call Transcript - Seeking AlphaReNeuron Group's (RNUGF) CEO Olav Hellebø on Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - December 15 at 11:28 AM
ReNeuron Group (RENE) Announces Quarterly  Earnings ResultsReNeuron Group (RENE) Announces Quarterly Earnings Results
www.americanbankingnews.com - December 14 at 8:58 AM
ReNeuron opens US office - London South East (blog)ReNeuron opens US office - London South East (blog)
www.lse.co.uk - December 8 at 3:59 PM
ReNeuron Group Plc (RENE) Given "corporate" Rating at N+1 SingerReNeuron Group Plc (RENE) Given "corporate" Rating at N+1 Singer
www.americanbankingnews.com - October 31 at 9:54 AM
ReNeuron Reports Positive Long Term CTX Cell Data In Stroke DisabilityReNeuron Reports Positive Long Term CTX Cell Data In Stroke Disability
www.morningstar.co.uk - October 31 at 8:33 AM
Wins further UK grantWins further UK grant
www.lse.co.uk - October 27 at 7:03 PM
ReNeuron Wins Stake In GBP1.2 Million Grant For Therapy PlatformReNeuron Wins Stake In GBP1.2 Million Grant For Therapy Platform
www.morningstar.co.uk - October 27 at 7:03 PM
ReNeuron Presents Positive ExoPr0 CTX Data At San Francisco ConferenceReNeuron Presents Positive ExoPr0 CTX Data At San Francisco Conference
www.morningstar.co.uk - October 10 at 6:21 AM
ReNeuron Group Plc (RENE) Receives corporate Rating from N+1 SingerReNeuron Group Plc (RENE) Receives corporate Rating from N+1 Singer
www.americanbankingnews.com - October 9 at 7:34 PM
One Thing To Consider Before Buying ReNeuron Group plc (AIM:RENE)One Thing To Consider Before Buying ReNeuron Group plc (AIM:RENE)
finance.yahoo.com - October 6 at 6:10 AM
Non-executive Director Appointment - London South East (registration) (blog)Non-executive Director Appointment - London South East (registration) (blog)
www.lse.co.uk - September 2 at 8:03 AM
Edison Issues Update on ReNeuron Group (RENE)Edison Issues Update on ReNeuron Group (RENE)
finance.yahoo.com - July 6 at 8:26 AM
ReNeuron Group Plc (LON:RENE) Earns Buy Rating from N+1 SingerReNeuron Group Plc (LON:RENE) Earns Buy Rating from N+1 Singer
www.americanbankingnews.com - July 2 at 7:14 AM
Id ditch ReNeuron Group plc to buy another Neil Woodford favourite - Motley Fool UKI'd ditch ReNeuron Group plc to buy another Neil Woodford favourite - Motley Fool UK
www.fool.co.uk - June 30 at 6:05 AM
UK Stocks-Factors to watch on June 29 - ReutersUK Stocks-Factors to watch on June 29 - Reuters
www.reuters.com - June 29 at 6:31 AM
ReNeuron Gets US Approval For Cryopreserved Formulation Of TherapeuticReNeuron Gets US Approval For Cryopreserved Formulation Of Therapeutic
www.morningstar.co.uk - June 20 at 2:19 AM
ReNeuron To Present CTX Exosome Candidate Data At London ConferenceReNeuron To Present CTX Exosome Candidate Data At London Conference
www.morningstar.co.uk - May 5 at 7:45 PM
Half Year 2016 ReNeuron Group PLC Earnings Release - Before Market OpenHalf Year 2016 ReNeuron Group PLC Earnings Release - Before Market Open
biz.yahoo.com - February 10 at 10:28 PM
DIRECTOR DEALINGS: ReNeuron CFO Buys 250,000 SharesDIRECTOR DEALINGS: ReNeuron CFO Buys 250,000 Shares
www.morningstar.co.uk - February 7 at 8:21 AM
Evgen Pharma Doses First Breast Cancer Trial Patients; Hires New CFOEvgen Pharma Doses First Breast Cancer Trial Patients; Hires New CFO
www.morningstar.co.uk - January 17 at 12:18 PM

SEC Filings

ReNeuron Group (LON:RENE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

ReNeuron Group (LON RENE) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.